CounterX Therapeutics to Present at 88th CPDD Scientific Meeting
CounterX Therapeutics, a biotech firm specializing in glutamate modulation therapies, will unveil Phase IIa clinical trial data at this week’s 88th Annual College on Problems of Drug Dependence (CPDD) meeting ... Read More